Published in Cancer Weekly, August 5th, 1996
After U.S. Food and Drug Administration (FDA) approval, Oncor has planned to market the blood test as a companion to conventional mammograms of women at high risk for the disease. "The p43 test detects an early immunological event in the body's response to the development of primary breast cancer that can be measured in patient blood, particularly with respect to women at high risk for breast cancer," said Chaya Moroz, Ph.D., Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.